Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Guardant360 CDx assay is the first liquid biopsy companion diagnostic test that uses next-generation sequencing technology to receive FDA approval. The assay uses NGS technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login